tldrdaily.news logo

Merck's Keytruda Gains EU and US Approvals for New Formulations and Indications

1 min read
Source: Merck.com
Merck's Keytruda Gains EU and US Approvals for New Formulations and Indications
Photo: Merck.com
TL;DR Summary

Merck received positive EU CHMP opinions for its cancer drug KEYTRUDA, including approval for subcutaneous administration and a new indication for earlier-stage head and neck cancer, potentially expanding treatment options in Europe.

Topics:business#cancer-treatment#eu-approval#healthcare#immunotherapy#keytruda#merck
Share this article
  1. Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer  Merck.com
  2. FDA OKs New Keytruda Shot for Cancer  The New York Times
  3. US FDA approves Merck's new injectable version of Keytruda  Reuters
  4. Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications  OncLive
  5. Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season  Business Wire

Reading Insights

Total Reads

1

Unique Readers

3

Time Saved

48 min

vs 48 min read

Condensed

100%

9,538 → 32 words

Want the full story? Read the original article

Read on Merck.com